In the context of ALS–CSF–mediated disease, we show that E6 antibody slightly reduced NFκB activation in the brain of ALS–CSF–treated mice (Fig. 8e) without remarkably affecting microgliosis (Fig. 8b–c). The gene discussed is NFKB1; the disease is amyotrophic lateral sclerosis.